Revista Española de Cardiología - Suplemento - vol 20 ; fasc B ; 2020

M. Anguita et al. / Rev Esp Cardiol Supl. 2020; 20(B) :1-46 43 136. Senni MWR, Witte K, Straburzynska-Migaj E, et al. Initiation of sacubitril/ valsartan in patients with de novo heart failure with reduced ejection fraction: an analysis of the TRANSITION study. Heart Failure 2019-6th World Congress on Acute Heart Failure. Atenas, 2019. 137. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019. 138. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. 139. Januzzi JL Jr, Prescott MF, Butler J, et al. Association of change in N-terminal pro- B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA . 2019;315:1-11. 140. Abi Khalil C, Sulaiman K, Mahfoud Z, et al. Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East. BMJ Open. 2017;7:e014915. 141. Ahn MS, Yoo BS, Yoon J, et al. Prognostic effect of guideline-directed therapy is more noticeable early in the course of heart failure. J KoreanMed Sci. 2019;34:e133. 142. DeFilippis E, Butler J, Vaduganathan M. Waiting period prior to ICD implantation in newly-diagnosed HFrEF: A window of opportunity. Circ Heart Fail. 2017;10:1-7. 143. Pascual-Figal D, Bayes-Genis A. The misperception of ‘stable’ heart failure. Eur J Heart Fail. 2018;20:1375-1378. 144. Goode KM, Nabb S, Cleland JG, Clark AL. A comparison of patient and physician- rated New York Heart Association class in a community-based heart failure clinic. J Card Fail. 2008;14:379-387. 145. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007;115:1563-1570. 146. Dini FL, Guglin M, Simioniuc A, et al. Association of furosemide dose with clinical status, left ventricular dysfunction, natriuretic peptides, and outcome in clinically stable patients with chronic systolic heart failure. Congest Heart Fail. 2012;18:98-106. 147. Sargento L, Simoes AV, Longo S, Lousada N, Reis RP. Furosemide prescription during the dry state is a predictor of long-term survival of stable, optimally medicated patients with systolic heart failure. J Cardiovasc Pharmacol Ther. 2017;22:256-263. 148. Pellicori P, Cleland JG, Zhang J, et al. Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther. 2016;30:599-609. 149. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21:365-371. 150. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116:1242-1249. 151. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528-1538. 152. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor- neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990-1997. 153. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72: 351-366. 154. Franciosa JA, Massie BM, Lukas MA, et al. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J. 2004;148:718-726. 155. Marti CN, Fonarow GC, Anker SD, et al. Medication dosing for heart failure with reduced ejection fraction — Opportunities and challenges. Eur J Heart Fail. 2019;21:286-296. 156. Komajda M, Bohm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018;20:1315-1322. 157. EMA. Entresto, INN-sacubitril/valsartan [ficha técnica o resumen de las características del producto]. 2015. Disponible en: https://www.ema.europa.eu/ en/documents/product-information/entresto-epar-product-information_es.pdf. Consultado 3 Feb 2020. 158. Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6:489-498. 159. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61. 160. Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18:1193-1202. 161. Senni M, Wachter R, Witte K, et al. In-hospital initiation of sacubitril/valsartan in stabilised patients with heart failure and reduced ejection fraction naïve to renin-angiotensin system blocker: An analysis of the TRANSITION study. Heart Failure 2019-6th World Congress on Acute Heart Failure. Atenas, 2019. 162. Ambrosy AP, DeVore A, Morrow D, et al. Prior exposure to a conventional renin- angiotensin systema antagonist and angiotensin receptor-neprilysin inhibition in acute decompensated heart failure: a prespecified subgroup anlalysis the PIONEER-HF trial. J Am Coll Cardiol. 2019;73. 163. Morrow DA, Velazquez E, DeVore A, et al. Effect of sacubitril/valsartan on biomarkers of myocardial stress in patients hospitalized with acute heart failure in PIONEER-HF. J Am Coll Cardiol. 2019;73. 164. DeVore A, Morrow D, Braunwald E, et al. Effect of sacubitril/valsartan on readmissions after a hospitalization for acute decompensated heart failure: a secondary analysis of the PIONEER-HF trial. J Am Coll Cardiol. 2019;73. 165. DeVore AD, Braunwald E, Morrow DA, et al. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: results of the open-label extension of the PIONEER-HF trial. J Am Coll Cardiol. 2019;73. 166. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—Concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582. 167. Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111:3411-3419. 168. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738-3744. 169. Gold MR, Daubert C, AbrahamWT, et al. The effect of reverse remodeling on long- term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015;12:524-530. 170. Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;315:1-10. 171. Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019;139:1354-1365. 172. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J . 2014;35:455-469. 173. Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6:547-554. 174. Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson LA, Tomson CR. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105:904-910. 175. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9. 176. Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Angiotensin- converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011;(1):CD007751. 177. Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. JACC Heart Fail. 2019;7:371-382. 178. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol. 1990;66:40D-44D; discussion 4D-5D. 179. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678. 180. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064-1073. 181. Edner M, Benson L, DahlstromU, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;36:2318-2326. 182. Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791. 183. Rangaswami J, McCullough PA. Heart failure in end-stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies. Semin Nephrol. 2018;38: 600-617. 184. Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7:573-579. 185. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60:2082-2089. 186. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. 187. Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37:2105-2114. 188. Hsu S, Bansal N. Updates in the management of heart failure for the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2019;28:262-266. 189. Inampudi C, Parvataneni S, Morgan CJ, et al. Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular